Vertex's Kalydeco, which was first approved in 2012, has received the FDA nod for an expanded indication that will provide a Cystic Fibrosis treatment for children ages four months to less than six months old.
The Lilly Diabetes Solution Center can provide significant savings on Lilly insulins. Anyone who uses a Lilly insulin can contact the Lilly Diabetes Solution Center to see whether one of the additional insulins, the Lilly Insulin Value Program or another affordability option is the best financial choice for them.
Roche's Gavreto is indicated for the treatment of adults with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA-approved test.
Novartis’ Kesimpta can now be self-administered at home, offering an easier way for patients to administer the treatment for relapsing forms of multiple sclerosis.
Bausch Health will establish two separate companies, one that will focus on eye health, and a pharmaceutical company that will focus on gastroenterology, aesthetics/dermatology, neurology and international pharma.
